...
首页> 外文期刊>Drug discovery today >Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress.
【24h】

Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress.

机译:颗粒药物载体在肿瘤治疗中的主动靶向作用:基本原理和最新进展。

获取原文
获取原文并翻译 | 示例
           

摘要

Drug therapy for the treatment of tumors is often limited by a narrow therapeutic index. One approach that overcomes this limitation is the active targeting of tumors with particulate drug carriers. The derivatization of particulate drug carriers with a ligand leads to the selective targeting of the particulate to selected cells, thereby focusing drug delivery. In addition, particulate drug carriers have a high loading capacity, do not need covalent conjugation of the drug and the formulation protects the entrapped drug from enzymatic inactivation. Despite these favorable properties, their therapeutic efficacy in animal models has been reported only in recent years. The use of internalizing ligands and the targeting of intravascular tumor cells and endothelial cells of tumor blood vessels have been instrumental in demonstrating the clinical effectiveness of particulate drug carriers in animal models. As a result, several actively targeted particulate carriers have now entered, or are about to enter, clinical investigation. Recent findings, for example, the identification of cell-penetrating peptides with restricted cell selectivity, suggest that further improvements in this approach are likely in the near future.
机译:用于治疗肿瘤的药物疗法通常受到狭窄的治疗指数的限制。克服这一局限性的一种方法是使用颗粒状药物载体主动靶向肿瘤。颗粒药物载体与配体的衍生作用导致颗粒选择性靶向选定的细胞,从而集中了药物的输送。另外,颗粒状药物载体具有高的负载能力,不需要药物的共价结合,并且该制剂保护了被包埋的药物免于酶灭活。尽管具有这些有利的性质,但仅在最近几年才报道了它们在动物模型中的治疗功效。内化配体的使用以及肿瘤血管的血管内肿瘤细胞和内皮细胞的靶向已经在证明颗粒状药物载体在动物模型中的临床有效性中发挥了作用。结果,几种主动靶向的颗粒载体现已进入或即将进入临床研究。最近的发现,例如鉴定具有有限细胞选择性的穿透细胞的肽,表明在不久的将来该方法可能会进一步改进。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号